Endotis Pharma presents data on the neutralizable anticoagulant EP217609 in an extracorporeal circulation model
Endotis Pharma presented that initial results on the neutralizable anticoagulant EP217609 in a canine model of extracorporeal circulation (ECC) at the French Society of Thoracic and Cardiovascular Surgery's 63th annual meeting in Tours, France.
Both EP217609 and its specific antidote avidin were well tolerated in this clinically relevant animal study. A single dose of EP217609 resulted in efficient, stable anticoagulation throughout the ECC procedure. Subsequent administration of avidin produced rapid, complete, irreversible neutralization and no rebound effect. There was no evidence of clotting in the extracorporeal circuits.
EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized by a specific antidote avidin (EP5001). EP217609 has a dual mechanism of action which combines direct (free and clot-bound) thrombin inhibition and indirect factor Xa inhibition.
In April, Endotis announced that EP217609 and its specific antidote avidin had successfully completed their respective first-in-man Phase I clinical trials and that a study assessing the neutralization of EP217609 by avidin in healthy subjects will be initiated this summer.
Endotis Pharma announced that it has successfully completed the first study assessing in healthy subjects the neutralization of the anticoagulant EP217609 by its specific antidote avidin.
EP217609 and avidin were well tolerated in the 36 healthy subjects enrolled in this study. A single in ... more
Endotis Pharma announced that Phase I clinical trial results for EP217609 were presented at the
21st International Congress on Thrombosis (ICT) in Milan, Italy. EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized by a specific antidote, avidin. EP217609 ... more
Endotis Pharma announced that the neutralizable anticoagulant EP217609 and its specific antidote avidin have successfully completed their respective first-in-man Phase I clinical trials.
EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized with a specif ... more
Founded in 2003, Endotis Pharma is a specialty pharma company dedicated to the discovery and development of small-glyco drugs (SGDs) for applications in thrombosis and oncology. Endotis Pharma has built a well-balanced portfolio of pre-clinical and clinical stage compounds, either in-licen ... more